- December 2021:
Application of the Union’s pharmaceutical acquis in markets historically dependent on medicines supply from or through parts of the United Kingdom other than Northern Ireland - December 2021:
Derogations from certain obligations concerning certain medicinal products for human use made available in the United Kingdom in respect of Northern Ireland, as well as in Cyprus, Ireland and Malta - December 2021:
Derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta - December 2021:
Derogation from the obligation of wholesalers to decommission the unique identifier of medicinal products exported to the United Kingdom - March 2021:
Derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom - January 2021:
Application of the Union’s pharmaceutical acquis in markets historically dependent on medicines supply from or through Great Britain after the end of the transition period - July 2020:
Joint EC/EMA/HMA technical notice - Clinical trials - June 2020:
Supplementary protection certificates - Medicinal products and plant protection products - May 2020:
EU rules - Clinical trials - March 2020:
EU rules - Medicinal products for human use and veterinary medicinal products
More information
- Notices in all EU linguistic on Getting ready for the end of the transition period